IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. Aging is a major risk factor for progression of IgAN to end stage renal disease. The purpose of this study was to identify and verify aging-related genes associated with IgAN through bioinformatics analysis. Microarray datasets of GSE93798 and GSE37460 were downloaded from the Gene Expression Omnibus (GEO) database. The aging-related DEGs (AR-DEGs) associated IgAN was analyzed by R programming software, and then genome ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed. The PPI network of AR-DEGs was then contructed, and hub genes were ranked using five methods of the cytoHubba plugin in Cytoscape software. CIBERSORT algorithm was used to evaluate the infiltrating immune cells and their relationship with hub genes. Next, Nephroseq V5 online platform was used to verify and analyze the mRNA expression patterns of hub genes in IgAN patients and normal controls.A total of 372 DEGs were identified, of which the expression of 158 were upregulated and 214 were downregulated. GO and KEGG enrichment pathway analysis mainly focused on regulation of macrophage derived foam cell differentiation, PI3K-Akt signaling pathway. Based on the results of PPI network analysis, the eight hub genes were identified, including AGT, ALB, CD36, EGF, KDR, LPL, MYC, PPARGC1A. Immunoinfiltration analysis indicated that CD36 were closely related to immune cell infiltration. Furthermore, the expression levels of these hub genes were validated using the Nephroseq V5 online platform. Further clinical sample studies confirmed that CD36 was highly expressed in renal tissues of IgAN patients. These findings provide new insights into potential aging-related genes associated with IgAN, which may better contribute to understanding the pathogenesis of IgAN. CD36 may have diagnostic value for aging-related IgAN.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Medical Ethics Committee of the Second People's Hospital of Hefei

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are within the manuscript and its Supporting Information files.